Enter to open, tab to navigate, enter to select
Antitrust risk-shifting provisions in Wright Medical Group, Inc./BioMimetic Therapeutics, Inc. merger agreement
| November 19, 2012 • Antitrust Risk-shifting • $190 million (excluding contingent value rights of up to $190 million). |
End of Document
© 2024 Thomson Reuters. No claim to original U.S. Government Works.